Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

7.250 -0.410 (-5.35%)
Streaming Delayed Price Updated: 12:18 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 ↗
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
News headline image
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings ↗
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 ↗
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
News headline image
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023 ↗
 
Via Benzinga
News headline image
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views ↗
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The... 
Via Benzinga
Topics Earnings Stocks
News headline image
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.